26 March 2021 in European Heart Journal
Activity in the amygdala, a brain centre involved in the perception of and response to stressors, associates with: (i) heightened sympathetic nervous system and inflammatory output and (ii) risk of cardiovascular disease. We hypothesized that the amygdalar activity (AmygA) ratio is heightened among individuals who develop Takotsubo syndrome (TTS), a heart failure syndrome often triggered by acute stress. We tested the hypotheses that (i) heightened AmygA precedes development of TTS and (ii) those with the highest AmygA develop the syndrome earliest. Individuals (N=104, median age 67.5 years, 72% female, 86% with malignancy) who underwent clinical 18 F-FDG-PET/CT imaging were retrospectively identified: 41 who subsequently developed TTS and 63 matched controls (median follow-up 2.5 years after imaging). AmygA was measured using validated methods. Individuals with (vs. without) subsequent TTS had higher baseline AmygA (P=0.038) after adjusting for TTS risk factors. Further, AmygA associated with the risk for subsequent TTS after adjustment for risk factors [standardized hazard ratio (95% confidence interval): 1.643 (1.189, 2.270), P=0.003]. Among the subset of individuals who developed TTS, those with the highest AmygA (>mean + 1 SD) developed TTS ∼2 years earlier after imaging vs. those with lower AmygA (P=0.028). Higher AmygA associates with an increased risk for TTS among a retrospective population with a high rate of malignancy. This heightened neurobiological activity is present years before the onset of TTS and may impact the timing of the syndrome. Accordingly, heightened stress-associated neural activity may represent a therapeutic target to reduce stress-related diseases, including TTS. Relationship between stress-associated neurobiological activity on 18F-FDG-PET/CT imaging and risk for subsequent Takotsubo syndrome. 18F-FDG-PET/CT, 18F-fluorodeoxyglucose positron emission tomography/computed tomography; TL, temporal lobe; TTS Takotsubo syndrome; vmPFC, ventromedial prefrontal cortex.
14 February 2021 in European Heart Journal
Air pollution [i.e. particulate matter with diameter <2.5 μm (PM2.5)] is a risk factor for major adverse cardiovascular events (MACE). While PM2.5 promotes leucopoiesis and atherosclerotic inflammation in experimental models, it is unknown whether this occurs in humans. We tested in humans (a) whether PM2.5 associates with higher leucopoietic tissue activity and arterial inflammation (ArtI), (ii) whether these associations persist after accounting for the effects of potential confounders including socioeconomics, traffic noise, and risk factors, and (iii) whether these tissue effects mediate the association between air pollution and MACE. Individuals (N = 503) without cardiovascular disease (CVD) or active malignancy underwent 18 F-fluorodeoxyglucose positron emission tomography/computed tomography. Major adverse cardiovascular event was adjudicated over 5 years of follow-up. Leucopoietic tissue activity (in bone marrow and spleen) as well as ArtI were measured. Annual PM2.5 levels were assessed at each individual’s home address. At baseline, higher PM2.5 associated with increased leucopoietic activity [standardized (95% CI): 0.129 (0.042, 0.215), P = 0.004] as well as ArtI [0.088 (0.006, 0.171), P = 0.036] after adjusting for CVD risk factors. Over a median 4.1 years, 40 individuals experienced MACE. PM2.5 exposure associated with MACE [Cox HR (95% CI): 1.404 (1.135, 1.737), P = 0.002], remaining significant after adjustment for CVD risk factors and other potential confounders. Mediation analysis demonstrated that increased leucopoietic activity and ArtI serially mediate the link between PM2.5 exposure and MACE. Higher air pollution exposure associates with heightened leucopoietic activity and ArtI and independently predicts MACE through a biological pathway that includes higher leucopoietic activity and ArtI in series. The hypothesized mechanism linking air pollution exposure to major adverse cardiovascular disease events through an up-regulated leucopoietic-arterial axis (solid red arrows).
12 February 2025 in JACC: Case Reports
We present a case of transcatheter aortic valve replacement in a 70-year-old woman with severe bicuspid aortic valve stenosis complicated by incomplete recapture of the Evolut valve and buckling of the delivery system. Our key steps included the following: 1) unsuccessful withdrawal of the buckled delivery system and valve into the inline sheath; 2) transradial snaring of the delivery system, followed by traction from both ends to reduce the amount of buckling; and 3) once elongated as much as possible, the malfunctioning Evolut delivery system and valve were removed as a unit over the wire. Aortic, iliac, or femoral injury: Reliant balloon was placed in the distal aorta use in case of arterial rupture. The Evolut delivery system can buckle and accordion under tension in complex aortic anatomy. A technique of snaring from above and tension from below can mitigate the buckled area and allow removal of the damaged delivery system via the endovascular route.
25 June 2025 in JACC: Case Reports
We present a case of ViV-TAVR in an 85-year-old female with severe bioprosthetic aortic valve stenosis at a high risk of left and right coronary artery obstruction. This risk was mitigated by a procedure combining both BASILICA and UNICORN (BABICORN - Bileaflet Alteration with BASILICA and Iatrogenic Cusp Obliteration using Radiofrequency Needle) for double leaflet modification. Key steps: • Electrosurgical traversal of the right leaflet and creating the electrosurgical loop using 2 guide catheters and an Astato wire within • Electrosurgical traversal of the left leaflet and ballooning the leaflet fenestration. • Creating the flying V and lacerating the right leaflet. • Serial ballooning and ultimately lacerating the left leaflet. • Deployment of the Evolut valve. Catheter entanglement, inadequate leaflet laceration and stroke or systemic embolization. The BABICORN procedure for double leaflet modification before ViV-TAVR with a self-expanding valve is technically feasible and preserves coronary flow in both native arteries.
25 October 2025 in JACC: Cardiovascular Interventions
9 December 2025 in Baylor University Medical Center Proceedings
The use of mechanical circulatory support (MCS) devices with transcatheter aortic valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (mTEER) is occasionally required; however, outcomes data are lacking. We utilized the Nationwide Inpatient Sample database to identify hospital admissions of adults treated with TAVR and mTEER, with or without MCS, between 2018 and 2021. We identified 330,055 patients undergoing TAVR and mTEER, with 3240 in the MCS group and 326,815 in the non-MCS group. From 2018 to 2021, there was a steady increase in procedural volume (P for trend <0.001). Utilization of MCS remained stable (P for trend: total 0.096). The use of any MCS modality was associated with a >26-fold increase in mortality (1.01% vs 26.82%, P < 0.001). Mortality remained steadily high with MCS use (P for trend = 0.08). Length of stay and cost of hospitalization were higher in the MCS group (P < 0.05 for both). The use of MCS in patients undergoing TAVR or mTEER was associated with higher mortality, morbidity, and healthcare utilization; however, causation cannot be determined given the inherent limitations of the dataset.